WINDTREE THERAPEUTICS INC (WINT)

Company Profile

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 20 full-time employees. The firm is focused on the development of therapeutics intended to address unmet medical needs in important cardiovascular care markets. The Company’s development programs are primarily focused on the treatment of cardiovascular diseases. Its lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients to treat early cardiogenic shock and acute heart failure (AHF). Its Rostafuroxin is an investigational drug product candidate being developed for the treatment of hypertension in patients with a specific genetic profile. Its heart failure cardiovascular portfolio also includes sarco endoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) activators. The firm is also conducting early exploratory research to assess potential product candidates, including oral and intravenous SERCA2a activator heart failure compounds.

Company Info

WINDTREE THERAPEUTICS INC

2600 Kelly Rd Ste 100

Warrington PENNSYLVANIA 18976

P: 12154889300

CEO: Craig E. Fraser

Employees: 20

Website: https://windtreetx.com/